Evaluation of oxidative stress after repeated intravenous iron supplementation.
Parenteral iron has been recommended for the treatment of iron deficiency in the majority of maintenance hemodialyzed (HD) patients. However, iron supplementation and consequent over saturation of transferrin and high iron levels, may aggravate oxidative stress already present in these patients. This study aimed to further clarify the role of repeated intravenous iron therapy as a supplementary cause of oxidative stress in HD patients. Markers of free radical activities (carbonyl reactive derivatives, CRD, thiol groups, SH, malondialdehyde, MDA) and antioxidant enzyme activities (superoxide dismutase, SOD and glutathione peroxidase, GPX) were determined in plasma and red blood cells (RBC) of 19 hemodialysis patients given a total iron dose of 625 mg (ferrogluconat, Ferrlecit, 62.5 mg). Blood samples were taken before the first and after the last dose of iron. Twenty apparently normal subjects served as healthy controls. Before iron treatment, HD patients exhibited increased concentrations of MDA and CRD in plasma and red blood cells, accompanied with impaired antioxidant capacity. All patients responded to iron therapy with a significant increase in their serum ferritin, serum iron, hemoglobin, and red blood cells levels. However, iron treatment resulted in enhanced oxidative stress in plasma of HD patients, since significant increase in plasma MDA and CRD concentrations, together with a decrease in nonprotein SH groups levels were detected. Supplementation with iron did not significantly influence plasma SOD and GPX activities, nor did any of the red blood cell parameters tested. Our data show that, despite improvement in hematological parameters, an increase in iron stores due to supplementation could also contribute to increased free radical production in HD patients.
Mimić-Oka
Jasmina
J
Institute of Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia and Montenegro. okasn@ptt.yu
Savić-Radojević
A
A
Pljesa-Ercegovac
M
M
Opacić
M
M
Simić
T
T
Dimković
N
N
Simić
D V
DV
D000328:Adult; D000429:Alcohol Oxidoreductases / Q000097:blood; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D004334:Drug Administration Schedule; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage*; D005500:Follow-Up Studies; D005979:Glutathione Peroxidase / Q000097:blood; D006801:Humans; D007124:Immunoenzyme Techniques; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications; D015227:Lipid Peroxidation / Q000187:drug effects / Q000502:physiology; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology*; D013053:Spectrophotometry; D013482:Superoxide Dismutase / Q000097:blood; D014168:Transferrin / Q000378:metabolism; D016896:Treatment Outcome
D015415:Biomarkers; D005290:Ferric Compounds; D014168:Transferrin; D000429:Alcohol Oxidoreductases; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; C035552:ferric gluconate